- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
In the September 2017 Issue:
- Congress Extends Patient Protections to December
- DOJ Challenged by Congress on Cannabis Research Delays
- Maryland Approves Three More PFC-certified Companies
- PFC Trainings in Philly, New Webinar, California Conference
- ASA Educating State Officials at National Conference
- ASA Activist Profile: Valencia Elliott, Westchester, New York
- Action Alert: Sign the Petition on Ending the Opioid Crisis
Congress Extends Patient Protections to December
Federal protections for medical cannabis patients and providers have been extended another three months. The continuation comes courtesy of a continuing resolution that funds the federal government through December, keeping in place the Rohrabacher-Farr Amendment that is part of the Department of Justice (DOJ) funding for the year. The resolution cleared the Senate 80-17 on Thursday, with the House voting 316-90 in favor on Friday.
Since 2014, Rep. Dana Rohrabacher (R-CA) and a series of Democratic cosponsors have succeeded in including language in the annual spending bill that bars the DOJ from spending funds interfering with state medical cannabis laws. The courts have ruled that means federal prosecutors must show violations of state law to pursue federal marijuana charges against patients or providers.
The latest version has been included in the Senate version of the FY18 appropriations bill but was blocked in the House last week by Republican leaders. Despite an impassioned 35-minute floor speech in the House from Rep. Rohrabacher and an OpEd he penned in the Washington Post, the House Rules Committee prevented a vote on the Rohrabacher-Blumenauer Amendment, as well as a number of others related to cannabis. One member of the committee told reporters that GOP leaders were concerned votes on the cannabis amendments would split their caucus.
In 2014, the bipartisan amendment, then known as Rohrabacher-Farr for retired co-sponsor Rep. Sam Farr (D-CA), passed the House 219-189. It was attached to DOJ funding again in 2015 on a vote of 242-186. Since then, the amendment has been extended through omnibus spending legislation like the continuing resolution just passed.
If and when the House passes an appropriations bill for FY 2018, a conference committee would decide how to reconcile differences with the Senate version, including whether to include the Rohrabacher-Farr Amendment.
Reps. Rohrabacher and Earl Blumenauer (D-OR) issued a joint statement blasting the committee decision, saying it “is putting at risk the millions of patients who rely on medical marijuana.” The amendment names the 46 states and the District of Columbia that have legalized use and distribution of some form of medical marijuana.
Other blocked amendments include three that would have allowed licensed cannabis businesses to use financial service and one to facilitate medical cannabis research.
DOJ Challenged by Congress on Cannabis Research Delays
Concerned members of Congress are asking Attorney General Jeff Sessions to explain a reported move by the Department of Justice (DOJ) to halt cannabis research. The bipartisan group’s letter came after the Washington Post reported the DOJ was sitting on 22 applications to cultivate cannabis for research purposes.
The Drug Enforcement Administration (DEA) opened up applications a year ago. The DEA had resisted pressure to allow other sources for research cannabis than the one authorized farm run by the National Institute on Drug Abuse, which is notorious for producing poor quality cannabis and denying researchers access to it. Now it’s the DOJ that’s blocking progress and effectively shutting down research, according to anonymous DEA officials who have spoken with reporters.
The bipartisan letter signed by Reps. Earl Blumenauer (D-OR), Matt Gaetz (R-FL), Jared Polis (D-CO), and Dana Rohrabacher (R-CA) was made public by Tom Angell of MassRoots. Blumenauer, Polis and Rohrabacher are co-founders of the Congressional Cannabis Caucus.
Maryland Approves Three More PFC-Certified Companies
Three companies who are currently part of ASA’s Patient Focused Certification program were approved for licensing by Maryland’s Medical Cannabis Commission in August. Freestate Wellness, Harvest of Maryland, and Green Leaf Medical each received Stage 2 licenses to grow and process medical cannabis in Maryland, where program implementation delays have left patients suffering.
Before their state inspections, Freestate Wellness and Harvest of Maryland received a PFC inspection preparedness assessment to ensure their readiness. Pre-inspection services are a new offering this year from PFC to help medical cannabis businesses navigate the licensing process.
This PFC service includes a mock inspection with a PFC auditor, review of the state inspection checklist and a spot check of procedures for compliance. After the audit, companies receive a report on suggested corrective actions and an audit debrief.
Several of the companies that were approved last month also have PFC-trained employees. The PFC training program offers a range of certifications in different disciplines (cultivation, laboratory, distribution, manufacturing) intended for everyone from entry level staff to managers and regulators.
So far over 12,000 patients have signed up to become eligible for the Maryland medical cannabis program, and 400 medical providers have signed up to make recommendations. As of September 1st, Maryland has 12 growers, 6 processors, 1 dispensary, and 2 independent testing labs.
PFC will be hosting in-person trainings in Maryland, Philadelphia and the District of Columbia to help as many companies as possible gain Stage 2 licenses in the upcoming months. For info on upcoming trainings, please visit www.safeaccessnow.org/events. The Philadelphia training with PFC Director Jahan Marcu, PhD, will be September 18 and 19. PFC trainings are also available on-line on-demand.
PFC Trainings in Philly, New Webinar, California Conference
September is a busy month for ASA’s Patient Focused Certification program. On the 18th and 19th, Jahan Marcu, PhD, will be conducting a training in Philadelphia that meets the state’s requirements for training on operations. He’ll also be presenting the first training on extraction safety.
Dr. Marcu will also be representing PFC at the NCIA Cannabis Business Conference talking about the importance of standardized products that are safe and reliable. Among those who will be there are Lori Ajax, head of the California Bureau of Medical Cannabis Regulation and BDS Analytics, a long-time NCIA partner, which has released a trends report on California that you can read about in NCIA’s latest blog post. ASA members can use code PFC15 to save 15% on registration for the California Cannabis Business Conference this September 21-22 in Anaheim, California.
Earlier this month, PFC conducted a webinar with leading cannabis researcher, Ethan Russo, MD, talking about how cannabis can help ease the opioid crisis. Excerpts from that talk will be available on ASA’s youtube channel in two weeks, with full access for ASA members. Dr. Russo is the coauthor with Dr. Marcu of “Cannabis Pharmacology,” a chapter of a forthcoming book.
Dr. Marcu was also in Oregon last month at the Cannabis Science Conference delivering an invited talk on ASA and the endocannabinoid system. PFC has been offering a special promotion in Oregon for reduced cost or free laboratory certifications. PFC will be back in Oregon in October for more trainings and assessments. Find out dates and locations at www.safeaccessnow.org/events.
ASA Educating State Officials at National Conference
State policymakers got some education on medical cannabis policy and science last month. In early August, staff from Americans for Safe Access attneded the 2017 National Conference of State Legislators (NCSL) Legislative Summit in Boston, meeting with many of the 6,700 attendees.
As one of the largest annual gatherings of state legislators, legislative staff and government officials, the NCSL conference provided a prime opportunity to provide information on safe access to medical cannabis.
ASA distributed materials on how cannabis can ease the opioid crisis and provided briefing books to hundreds of state legislators. Americans for Safe Access staff were joined at the Conference by representatives from Safe Access Tennessee, led by David Hairston (pictured at right with ASA's governmental affairs director, Beth Collins).
“We had great conversations with legislators in states with well-established programs like Colorado, but more importantly we were able to change the minds of legislators in states such as South Dakota, Idaho and Kansas,” said ASA Legislative Analyst David Mangone. “We also had productive conversations with staff from the DEA and FDA.”
Three separate panels focused exclusively on cannabis, and each was standing room only. The cannabis panels on “Financial Services for Marijuana,” “Marijuana Federalism” and “Cannabis Crosses the Country” included state representatives, academics, and professionals from the cannabis industry.
ASA worked closely with the Health and Human Services Committee of NCSL on a resolution proposing the use of cannabis as a tool in mitigating the opioid crisis, which will be voted on later this year. A resolution calling for the rescheduling of cannabis was approved.
ASA Activist Profile: Valencia Elliott, Westchester, New York
Valencia Elliott grew up in what she calls a tough part of the country where she’d regularly smell cannabis being smoked, but she never had any interest in it. That changed late in life when her husband, an Army veteran who’d been exposed to Agent Orange during the Vietnam War, confided he had cancer. Worse, he’d been hiding a prostate cancer diagnosis for a year, and by the time he told her, he also had two other types of cancer. That was June 3, 2015, but the nightmare had already started. She didn’t know what was wrong, but they were already going back and forth to the hospital with complaints about his pain.
Her husband’s care through the Veterans Health Administration required lots of management, dealing with increasing pain and the effects of a misdiagnosis and surgery that didn’t heal. Soon, Valencia quit her job of 18 years in the health food industry so she could advocate for him. His situation spiraled quickly through rounds of radiation and chemotherapy that changed nothing.
“He did everything he was told but got no relief, no comfort.” says Valencia. “I don’t understand medical industry.”
So she got on the internet and started looking for alternatives. New York had just passed its restrictive medical cannabis law, but it was not yet fully operational. Valencia reached out to a doctor in Minnesota, and he put her in touch with Americans for Safe Access, who helped her with more information.
Since New York requires physicians who write recommendations in the state to have a special registration, and the program had just launched, there were very few doctors.
“It really was a process,” Valencia says. “I was just getting angrier.”
On March 11, 2016, New York state issued her husband a card. Now the problem was accessing quality medicine. She tried the most expensive strains and CBD oil. Nothing she could get seemed to be strong enough to control her husband’s pain.
Nor was it easy to get it to him. By now, he was in a care facility that was not supportive of using medical cannabis, so Valencia had to disguise the medicine she took him.
“I just wanted a better quality of life for my husband,” Valencia says. “It was a very traumatic way of dying.”
On May 1, 2016, Valencia’s husband passed away.
“If he’d had better access sooner, he wouldn’t have suffered as much,” says Valencia. “New York is very hard, very frustrating.”
Determined to learn more and make a difference for others, Valencia applied to ASA for a scholarship to attend the Unity Conference in Washington, D.C. last April. There she met advocates from all over the world and came away equipped with new contacts and information. From there, she went to Albany with the Drug Policy Alliance to lobby the New York state legislature for better laws and policies.
“I’m going back to work, looking for a job that will let me help open people’s eyes,” says Valencia. “We have more to learn, but this medicine can help people’s suffering,”
Action Alert: Sign the Petition to End the Opioid Crisis
Opioids claim the lives of 91 individuals every day. With nearly 60,000 overdose deaths in 2016, 60% of which were related to prescription opioids, it is clear that there is a major public health crisis in our country. That is why we are launching our End Pain Not Lives campaign.
In order to ensure that all possible tools are being utilized as part of the path forward to ending the crisis, we need President Trump to formally declare the opioid epidemic a national health emergency. Declaration of a national emergency frees up resources that public health officials and states can then use to help treat pain safely and ultimately end the epidemic.
Urge President Trump to make this official now by signing this petition!